Colorectal Cancer — Overview & Epidemiology
Colorectal cancer (CRC) is the 3rd most common cancer globally and a rapidly rising concern across the GCC. Distinct epidemiological features set Gulf patients apart from Western counterparts.
GCC Epidemiology
- Median age at diagnosis: ~52 years in Saudi Arabia vs ~68 in Western countries
- Rising incidence across all GCC nations — dietary westernisation, sedentary lifestyle
- High proportion present at Stage III/IV due to late symptom recognition
- Male predominance (M:F ~1.4:1)
- Colon cancer slightly more common than rectal in GCC registry data
Why Late Presentation?
- Cultural normalisation of symptoms (e.g., rectal bleeding attributed to haemorrhoids)
- Reluctance to discuss bowel symptoms — perceived taboo
- Limited community-based screening uptake
- Symptoms dismissed by primary care or patient
- Delayed colonoscopy access in some regions
Risk Factors
Dietary & Lifestyle
- Low-fibre diet (refined carbohydrates common in GCC diet)
- High red and processed meat consumption
- Obesity — BMI >30 significantly increases risk
- Physical inactivity / sedentary lifestyle
- Diabetes mellitus type 2
- Smoking and alcohol (alcohol less prevalent in GCC but smoking high)
GCC-Specific Risk Factors
- Consanguinity: Higher rates of consanguineous marriage in GCC → increased autosomal recessive and dominant hereditary syndromes
- Lynch Syndrome (HNPCC): MMR gene mutations (MLH1, MSH2, MSH6, PMS2) — family cascade essential
- FAP (Familial Adenomatous Polyposis): APC gene mutation — prophylactic colectomy
- IBD (Ulcerative colitis / Crohn's) — risk increases with duration and extent
- Previous colorectal adenomas (sessile serrated / tubulovillous)
TNM Staging System
| T Stage | Description |
|---|
| T1 | Invades submucosa |
| T2 | Invades muscularis propria |
| T3 | Through muscularis into pericolorectal tissue |
| T4a/b | Perforates visceral peritoneum / invades adjacent organs |
| N Stage | Description |
|---|
| N0 | No regional node metastasis |
| N1 | 1–3 regional lymph nodes |
| N2 | ≥4 regional lymph nodes |
| M Stage | Description |
|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis present |
Stage grouping: I = T1-2N0M0 | II = T3-4N0M0 | III = any T N1-2 M0 | IV = any T any N M1
Clinical Presentation
Left Colon / Rectal
- Bright red rectal bleeding (BRBPR)
- Change in bowel habit — constipation/diarrhoea
- Tenesmus (sensation of incomplete evacuation)
- Narrow stools / ribbon stools
- Mucus per rectum
Right Colon
- Iron deficiency anaemia (occult blood loss)
- Fatigue and dyspnoea (anaemia)
- Right iliac fossa mass
- Vague abdominal discomfort
- Weight loss — late feature
Advanced / Metastatic
- Hepatomegaly / RUQ pain (liver mets)
- Cough / dyspnoea (lung mets)
- Jaundice
- Ascites (peritoneal disease)
- Pelvic pain / sciatic pain (pelvic recurrence)
Nursing Alert: In GCC practice, rectal bleeding is frequently misattributed to haemorrhoids. Educate patients that any rectal bleeding requires investigation, especially if associated with change in bowel habit or in patients over 40.
Investigations & Staging Workup
Diagnostic Investigations
- Colonoscopy: Gold standard — biopsy all lesions; full bowel survey for synchronous polyps/tumours
- CT Colonography: If incomplete colonoscopy (stricturing tumour)
- Flexible sigmoidoscopy: Urgent pathway for rectal symptoms
- FBC, LFTs, CEA: Baseline investigations; CEA pre-op for surveillance baseline
- MSI/MMR testing: All newly diagnosed CRC — implications for Lynch, prognosis, and immunotherapy eligibility
Staging Imaging
- CT chest/abdomen/pelvis (CT CAP): Standard staging for all CRC — assess liver, lung, peritoneum
- MRI rectum: Mandatory for all rectal cancers — assess mesorectal fascia involvement (MRF), EMVI, CRM
- PET-CT: Metastatic disease — assesses resectability of liver/lung mets; equivocal CT findings
- MRI liver: If liver metastases identified — assess resectability
- EUS: Early rectal tumours — T staging for local excision candidates
MDT Composition
The MDT meeting is mandatory prior to treatment planning. Core members include:
Colorectal SurgeonHepatobiliary Surgeon
Medical OncologistClinical Oncologist
RadiologistHistopathologist
Clinical Nurse Specialist (CNS)Stomatherapist
GastroenterologistPalliative Care
Nurse's role in MDT: The colorectal CNS coordinates patient information, attends MDT, communicates outcomes to patients, and is the patient's key worker throughout treatment. In GCC settings, language and cultural liaison is a critical nursing function.
Surgical Nursing Management
Colorectal surgery ranges from laparoscopic right hemicolectomy to abdominoperineal resection (APR). Nursing care is integral from prehabilitation through rehabilitation.
Bowel Preparation
Mechanical Bowel Prep (MBP)
- Macrogol (PEG) solution: 2–4L day before surgery; ensure IV access and hydration in elderly/renal impaired
- Sodium phosphate enemas: Rectal/sigmoid lesions; caution in renal failure and elderly
- Oral antibiotics: Neomycin + metronidazole — some ERAS protocols include for colon surgery
- MBP is standard for left-sided resections, rectal surgery, and colostomy reversal
- Right hemicolectomy: MBP not routinely required per ERAS guidance
Monitor for: electrolyte imbalance (especially sodium/potassium), dehydration, patient tolerance, and ensure adequate oral hydration or IV fluids during prep.
Pre-operative Nursing Assessment
- Stoma siting — stomatherapist marks optimal site pre-operatively (avoid skin folds, belt line, scars)
- Nutritional assessment — MUST score; consider pre-op nutritional support if malnourished
- Functional status — prehabilitation referral (exercise/physiotherapy)
- Pre-existing conditions — diabetes control (target HbA1c <8%), cardiac/respiratory risk
- Medication reconciliation — anticoagulants, NSAIDs, herbal supplements (black seed interactions)
- VTE risk assessment — TED stockings, LMWH plan post-op
- Smoking cessation — minimum 4 weeks pre-surgery
Enhanced Recovery After Surgery (ERAS) Protocol
| Phase | ERAS Element | Nursing Action |
|---|
| Prehabilitation | Exercise programme, nutritional optimisation, psychological support | Refer to physiotherapy; nutritional supplements if MUST ≥2; anxiety support |
| Pre-op | Carbohydrate loading | Oral carbohydrate drinks (200ml) 2–4 hrs pre-surgery; nil by mouth from midnight for solids only |
| Pre-op | Avoid prolonged fasting | Clear fluids up to 2 hours pre-surgery; educate patient and family |
| Intra-op | Goal-directed fluid therapy | Anticipate intra-op fluid restriction; post-op fluid balance management |
| Intra-op | Normothermia maintenance | Active warming blankets; monitor temperature post-op |
| Post-op | Early mobilisation | Sit out of bed Day 0–1; 2 hrs ambulation by Day 1; physiotherapy daily |
| Post-op | Early enteral feeding | Oral fluids 4–6 hrs post-op; soft diet Day 1; avoid prolonged NG feeding |
| Post-op | Multimodal analgesia | Epidural/wound infiltration + regular paracetamol + NSAIDs; minimise opioids (delay gut recovery) |
| Post-op | Avoid drains/catheters | Remove urinary catheter Day 1–2; avoid routine drains (if used — monitor output/character) |
| Post-op | VTE prophylaxis | LMWH from Day 1; TED stockings; mobilisation; extended prophylaxis 28 days for cancer patients |
Anastomotic Leak — Critical Nursing Monitoring
High Risk Window: Days 4–7 post-anterior resection. Anastomotic leak carries 15–25% mortality. Early nursing recognition is life-saving.
Early Warning Signs
- Tachycardia (HR >90) — often the first sign, even before fever
- Rising CRP — Day 3 CRP >150 mg/L is predictive; Day 5 CRP failing to fall is concerning
- Change in drain fluid — from serosanguinous to faeculent/turbid
- Increasing abdominal pain — disproportionate to expected post-op pain
- Fever >38.5°C — may be absent in immunosuppressed patients
- Failure to progress on ERAS pathway — "patient just not right"
- Falling urine output / septic shock in severe cases
Nursing Actions
- Escalate immediately to surgical team — do not delay
- IV access × 2; blood cultures × 2 sets; urgent bloods including CRP/WCC/lactate
- CT abdomen with rectal water-soluble contrast may be requested
- IV antibiotics as prescribed (piperacillin-tazobactam or meropenem per protocol)
- Fluid resuscitation — crystalloid 500ml bolus; reassess
- Nil by mouth; NG tube if distension
- Inform senior nurse/coordinator; document escalation time
- Prepare for potential emergency return to theatre
Stoma Formation — Types & Nursing Care
Loop Ileostomy
- Defunctioning stoma after low anterior resection (LAR)
- Protects anastomosis from faecal loading
- High output risk — up to 2–3L/day
- Monitor electrolytes daily initially
- Loperamide ± Codeine to slow output
- Reversal typically at 8–12 weeks
End Colostomy (Hartmann's)
- Hartmann's procedure — sigmoid colectomy, rectal stump oversewn
- May be reversed (Hartmann's reversal) — technically challenging
- Formed stool output — easier management
- Left iliac fossa siting standard
- Irrigation possible for selected patients
- Often permanent in elderly/unfit patients
APR — No Stoma, Perineal Wound
- Abdominoperineal resection — removes rectum and anus entirely
- End sigmoid colostomy — permanent
- Perineal wound — primary closure or flap
- Position: avoid prolonged sitting — pressure injury risk
- Perineal wound dehiscence common
- VAC (vacuum-assisted closure) therapy may be used
Stoma Nursing Priorities Post-op
- First 24–48 hrs: Inspect stoma colour (should be pink/red, moist) — dusky/black = ischaemia, escalate urgently
- Stoma should be active by Day 2–4 (wind first, then output)
- Bag change education — commence Day 1–2; aim independent by discharge
- Pouching system selection — flat vs convex vs soft-convex
- Skin barrier paste/rings for peristomal skin protection
- Peristomal skin complications — allergic contact dermatitis, leakage-related moisture associated skin damage
- Patient and family education — bag emptying, change technique, disposal
- Body image — psychological support, peer support networks
- Discharge planning — community stoma nurse referral, supplier registration
- Return to activities — driving, swimming, sports, Hajj/Umrah guidance
Post-APR Perineal Wound Care
- Perineal wound is at high risk of dehiscence — dead space, contamination, poor blood supply in radiated field
- Assess wound daily — note for signs of dehiscence, infection, or haematoma
- Negative pressure wound therapy (NPWT/VAC) — commenced intra-operatively in many centres; change every 3–5 days
- Sitz baths when wound has healed sufficiently — aids hygiene and comfort
- Position with caution — lateral or semi-prone preferred to sitting in early post-op period
- Pain management — perineal phantom pain may persist; gabapentin/neuropathic agents
- Sexual dysfunction counselling early — nerve damage during pelvic dissection
- Refer to pelvic physiotherapist for pelvic floor rehabilitation
GCC Climate Note: In hot, humid GCC climates, perineal wound moisture is a significant challenge. Moisture-wicking dressings, air conditioning, and more frequent wound assessment are essential to reduce complications.
Chemotherapy Nursing — Colorectal Cancer Protocols
Key regimens include FOLFOX, FOLFIRI, and oral capecitabine, often combined with targeted therapy (bevacizumab/cetuximab). Nursing vigilance for toxicity is paramount.
FOLFOX — Oxaliplatin + 5-FU + Leucovorin
Standard adjuvant chemotherapy for Stage III colon cancer (6 months); also used in metastatic CRC (mCRC) first-line.
Oxaliplatin Toxicity — Neuropathy
Acute cold-induced dysaesthesia: Occurs immediately after infusion. Cold food/drinks/surfaces trigger tingling/burning in hands, feet, and throat.
- Nursing instructions:
- Avoid cold food and drinks for 5–7 days after infusion
- Wear gloves to touch cold surfaces/air conditioning
- Avoid ice in drinks; warm all food to room temperature at minimum
- Warn patients about touching fridges/freezers or AC vents
- Throat dysaesthesia — reassure; not life-threatening but distressing
- Cumulative sensory neuropathy: Worsens with each cycle; persistent tingling/numbness/loss of fine motor skills
- Grade using CTCAE neuropathy scale at each cycle
- Dose reduction at Grade 2 persistent or Grade 3 neuropathy
- Stop oxaliplatin at Grade 3 — neuropathy may be irreversible
5-FU Toxicity
- Mucositis: Grade 1–2 common; maintain oral hygiene; mouthwash (benzydamine/chlorhexidine); soft diet; dose reduce Grade 3–4
- Diarrhoea: Monitor daily stool frequency; loperamide 4mg initial + 2mg each loose stool (max 16mg/day); IV hydration if Grade ≥3; stop chemo if severe
- Hand-Foot Syndrome (Palmar-Plantar Erythrodysaesthesia): Redness/peeling/pain hands and feet; moisturiser (urea-based); Grade 3 — dose reduce
- 5-FU cardiotoxicity: Coronary vasospasm — chest pain during infusion; STOP infusion immediately; ECG; notify oncologist. More common with continuous infusion
- DPD deficiency: DPYD genotype testing before 5-FU to identify at-risk patients for severe/fatal toxicity
Any chest pain during 5-FU infusion — STOP infusion immediately and call emergency team. 5-FU cardiotoxicity is potentially fatal.
Leucovorin (Folinic Acid)
Potentiates 5-FU activity. Given as IV infusion prior to 5-FU bolus. Minimal independent toxicity. Confirm correct dose prescribed (L-leucovorin vs DL-leucovorin — doses differ).
FOLFIRI — Irinotecan + 5-FU + Leucovorin
Used in mCRC (first or second line), often alternated with FOLFOX.
Irinotecan — Acute Cholinergic Syndrome
Onset during or within hours of infusion. Features: profuse watery diarrhoea, sweating, salivation, abdominal cramps, bradycardia, lacrimation.
- Treatment: Atropine 0.25–0.5mg IV/SC — have atropine available at bedside during all irinotecan infusions
- Pre-medicate with atropine if cholinergic syndrome occurred in prior cycle
- Reassure patient — acute, short-lived, treatable
- Document timing, severity, and treatment response
Irinotecan — Late Diarrhoea
Onset 24 hrs to 10 days post infusion. Can be severe and life-threatening if unmanaged (Grade 3–4 in up to 25% patients).
- Loperamide: 4mg at first loose stool, then 2mg every 2 hrs (day) / 4mg every 4 hrs (night) — maximum 16–24 hrs after last loose stool
- Octreotide 100–150mcg SC TDS: Refractory diarrhoea not responding to loperamide
- Oral rehydration — encourage 1–2L extra fluids
- If Grade 3–4 (>7 stools/day) or persistent — admit for IV hydration; hold irinotecan
- UGT1A1 genotyping — UGT1A1*28 homozygous at higher risk of severe toxicity; dose reduce first cycle
Irinotecan — Other Toxicities
- Neutropenia: Nadir Day 7–14; monitor FBC; G-CSF if required; febrile neutropenia protocol
- Alopecia: More prominent than with FOLFOX; counsel and offer scalp cooling/wig referral
- Nausea/vomiting: Moderate emetogenic potential; ondansetron + dexamethasone standard; aprepitant if not controlled
Capecitabine (Xeloda) — Oral Fluoropyrimidine
Oral prodrug of 5-FU. Used as adjuvant therapy (Stage III), combined with oxaliplatin (CAPOX), or as radiosensitiser in rectal cancer chemoradiotherapy.
Administration
- TWICE DAILY with food — reduces GI side effects and improves bioavailability
- Standard dose: 1000–1250 mg/m² BD; D1–14, rest D15–21 (3-weekly cycle)
- Take within 30 minutes of a meal
- Swallow whole with water — do not crush/split tablets
- Missed dose: skip and resume next scheduled dose — do not double up
- Storage: room temperature; moisture-free environment
Hand-Foot Syndrome (HFS) — Key Toxicity
- Grade 1: Redness/numbness/tingling — no dose change; emollient use
- Grade 2: Painful erythema limiting activities — dose reduce 25%
- Grade 3: Severe pain preventing daily activity — dose reduce 50% or hold
- Urea 10–20% cream — apply to palms and soles twice daily prophylactically from Day 1
- Avoid tight footwear, hot water, and repetitive pressure to palms/soles
- Cotton socks and gloves recommended
- Patient diary for HFS grading self-monitoring
Dose Reduction Thresholds: Grade 2 toxicity (any) on Day 1 of next cycle — delay until resolved to ≤Grade 1, then reduce by 25%. Any Grade 3–4 toxicity — hold until resolution, reduce by 25–50%. Maximum 3 dose reductions before discontinuation.
Drug Interaction: Capecitabine + Warfarin — significantly elevates INR (5-FU inhibits CYP2C9). Monitor INR frequently. Consider switching to LMWH for anticoagulation in patients on capecitabine.
Bevacizumab (Avastin) — Anti-VEGF Targeted Therapy
Added to FOLFOX or FOLFIRI in first-line mCRC. Inhibits angiogenesis.
Key Toxicities — Nursing Monitoring
- Hypertension: Most common — monitor BP at every cycle; antihypertensives if >150/100; hold if hypertensive emergency
- Wound healing impairment: Bevacizumab inhibits wound healing — MUST be held for 28 days before elective surgery and not restarted for 28 days post-operatively
- Bowel perforation: Rare (1–2%) but life-threatening — acute abdominal pain/peritonism — STOP bevacizumab immediately; emergency surgical referral
- Thromboembolism: Increased risk DVT/PE and arterial thrombosis (stroke/MI) — VTE prophylaxis; report chest pain/SOB/leg swelling immediately
- Proteinuria: Urine dipstick or spot protein:creatinine ratio before each cycle; hold if 2+ or >2g/24hr; stop if nephrotic syndrome
- Infusion reactions: Uncommon — hypersensitivity; observe during infusion
Pre-Cycle Checklist — Bevacizumab
- BP <150/100 mmHg before administration
- Urine protein dipstick ≤1+
- No recent surgery within 28 days
- No active bleeding or haemoptysis
- No GI perforation history in last cycle
- No uncontrolled hypertension
- Wound fully healed if previous surgery
Surgical coordination: Inform surgical team if patient is on bevacizumab — elective stoma reversal or other procedures require 28-day bevacizumab-free window minimum.
Radiotherapy Nursing — Rectal Cancer
Radiotherapy is central to rectal cancer management. Understanding treatment schedules and side effect management is essential for GCC oncology nurses.
Radiotherapy Schedules — Rectal Cancer
Short-Course Radiotherapy (SCRT)
- 5 × 5Gy over 1 week (25Gy total)
- Surgery within 1 week OR delayed 6–8 weeks (for tumour downstaging)
- Used for resectable tumours with clear MRF
- Acute toxicity relatively mild due to short duration
- Lower patient burden — important for GCC patients travelling long distances
- Increasingly used post-RAPIDO trial for high-risk rectal cancer followed by systemic chemotherapy
Long-Course Chemoradiotherapy (LCRT)
- 50.4Gy in 28 fractions over 5.5 weeks + concurrent capecitabine
- Surgery 6–8 weeks after completion (wait for tumour response/downstaging)
- Used for T3 MRF+ / T4 / N2 rectal tumours (threatened or involved MRF)
- Higher complete response rate (pCR ~15–20%) — potential watch-and-wait strategy
- Significantly more acute toxicity than SCRT
- Capecitabine BD on radiotherapy days only (Mon–Fri)
Skin Reactions — Acute Radiation Dermatitis
| Grade | Features | Nursing Management |
|---|
| Grade 1 | Faint erythema, dry desquamation, mild itch | Aqueous cream or emollient (unscented) to field; gentle washing; cotton underwear |
| Grade 2 | Moderate erythema, patchy moist desquamation, oedema | Moist wound healing dressings (e.g., hydrocolloid/foam); barrier film; silver dressings if infected |
| Grade 3 | Confluent moist desquamation, bleeding on trauma, significant pain | Wound care nurse input; possible treatment break; pain management; hygiene maintenance; no occlusive dressings over field during RT |
| Grade 4 | Skin necrosis, full-thickness ulceration | Treatment hold; surgical/wound team review; debridement; systemic antibiotics if infected |
Skin care instructions: No talcum powder, no deodorant/antiperspirant in radiation field. Use only prescribed emollients. Pat skin dry — do not rub. No tight clothing over treatment area. Avoid direct sunlight to treated skin.
Gastrointestinal Effects — Management
Radiation-Induced Diarrhoea
- Commences typically Week 2–3 of LCRT
- Loperamide: First-line — up to 8mg/day; titrate to response
- Low-fibre diet during treatment — reduces bowel urgency
- Adequate hydration — 2–2.5L/day; oral rehydration sachets if dehydrated
- Perianal skin care — barrier cream (zinc oxide/Cavilon) to prevent moisture-associated skin damage; especially in hot GCC climate
- Avoid high-fibre, spicy food, caffeine, alcohol during treatment
- Monitor electrolytes if severe (>4 stools/day above baseline)
Acute Radiation Proctitis
- Rectal urgency/frequency/bleeding/mucus — common during LCRT
- Steroid suppositories (prednisolone 5mg suppositories BD) — reduce mucosal inflammation
- Sucralfate enemas — mucosal protection in acute proctitis
- Distinguish from: infection (C. diff if antibiotics used), anastomotic issues
- Tenesmus management — antispasmodics (hyoscine butylbromide)
- Late radiation proctitis: months to years post-treatment — refer to gastroenterology; argon plasma coagulation for bleeding telangiectasia
Urinary Symptoms During Pelvic Radiotherapy
- Urinary frequency, urgency, dysuria — common from Week 2–3
- Exclude UTI first — MSU at first onset of urinary symptoms; treat empirically if unable to delay
- Encourage adequate hydration (paradoxically reduces irritant concentration)
- Avoid bladder irritants — caffeine, carbonated drinks, spicy food
- Alpha-blockers (tamsulosin) for urinary flow difficulty — especially in men with existing BPH
- Late effects — radiation cystitis: haematuria months post-treatment; refer urology for cystoscopy and hyperbaric oxygen therapy consideration
Sexual Dysfunction Post-Pelvic Radiotherapy
Women — Vaginal Effects
- Vaginal dryness and mucosal atrophy — commence from treatment completion
- Vaginal stenosis — fibrosis narrows vaginal canal; begins 6–12 weeks post-RT
- Vaginal dilators — commence 4–8 weeks post-RT; use 3× weekly; water-based lubricant
- Topical oestrogen (vaginal pessaries) — if not contraindicated (not systemic effect)
- Sexual health nurse/counsellor referral — often overlooked in GCC; culturally sensitive discussion required
- Dyspareunia — lubricants, dilator therapy, partner communication
Men — Erectile Dysfunction
- Radiation causes vascular and neurological damage to erectile tissues
- Onset gradual — may worsen over 1–2 years post-RT
- PDE5 inhibitors (sildenafil/tadalafil) — first-line; start early post-treatment
- Vacuum erection devices — non-pharmacological option
- Penile rehabilitation programme — maintain tissue oxygenation
- Urology/sexual health referral — discuss proactively; do not wait for patient to raise
- Retrograde ejaculation/anejaculation — counsel pre-treatment; sperm banking if relevant
GCC Cultural Sensitivity: Sexual health discussions require privacy, a same-gender nurse where possible, and awareness of cultural attitudes. Frame discussions around health outcomes and quality of life. Use trained interpreters not family members for these conversations.
Fatigue Management & Post-RT Surveillance
Radiation Fatigue
- Affects 70–90% during LCRT; peaks Week 3–5 and persists 4–6 weeks post-completion
- ESAS (Edmonton Symptom Assessment Scale) — screen at each fraction/week
- Pacing activities — balance rest and light activity
- Exercise: supervised walking programme reduces fatigue severity
- Treat contributing factors — anaemia (Hb <10 — consider transfusion); hypothyroidism; depression
- Sleep hygiene — avoid daytime napping >30 min
- Nutritional support — dietitian referral if weight loss >5% baseline
Post-Radiotherapy Surveillance
- MRI rectum 8–12 weeks post LCRT — assess tumour response
- Tumour response grading (TRG 1–5) — determines surgical plan or watch-and-wait eligibility
- Complete clinical response (cCR): MRI + endoscopy normal → watch-and-wait programme
- Watch-and-wait surveillance: MRI + flexible sigmoidoscopy every 3–4 months ×2 years, then 6-monthly
- Counsel on regrowth risk (~30% within 2 years in watch-and-wait) — early salvage surgery still possible
Survivorship & Surveillance
With improving treatment outcomes, more CRC patients are living beyond their cancer diagnosis. Structured survivorship care addresses ongoing physical, psychosocial, and functional needs.
Post-Treatment Surveillance Programme
| Investigation | Schedule | Purpose |
|---|
| CEA (carcinoembryonic antigen) | Every 3–6 months × 2 years, then 6-monthly × 3 years | Early detection of recurrence; rising CEA warrants CT CAP + PET |
| CT chest/abdomen/pelvis | 6–12 monthly × 3 years | Detection of liver, lung, lymph node recurrence |
| Colonoscopy | 1 year post-surgery, then 3-yearly if clear | Metachronous tumours; surveillance of remaining colon |
| MRI pelvis (rectal cancer) | 6-monthly × 2 years | Local recurrence detection after LAR/APR |
| Bloods (FBC/LFT/LDH) | With each surveillance visit | Detect haematological recurrence indicators |
CEA Limitations: 20–30% of CRC patients are CEA non-producers — a normal CEA does not exclude recurrence. Symptoms must always be investigated regardless of CEA level.
Low Anterior Resection Syndrome (LARS)
LARS affects up to 60–80% of patients after LAR — a cluster of bowel dysfunction symptoms that significantly impairs quality of life.
LARS Symptoms
- Frequency: Multiple bowel movements per day
- Urgency: Inability to defer defaecation
- Fragmentation: Multiple trips in short period
- Clustering: Several stools within 1 hour then long constipated intervals
- Incomplete evacuation
- Faecal incontinence (liquid stool)
- Nocturnal defaecation
- Flatus incontinence
LARS Score
5-item validated patient questionnaire (0–42 points): <21 = no LARS; 21–29 = minor LARS; 30–42 = major LARS. Use routinely in follow-up.
LARS Management
- Biofeedback therapy: Specialist physiotherapy — improves sphincter coordination; 6–8 sessions; evidence-based for major LARS
- Pelvic floor physiotherapy: Strengthening exercises; bowel retraining programme
- Dietary modification: High-fibre diet may worsen urgency; soluble fibre (Fybogel) to bulk stool; avoid gas-producing foods
- Loperamide: Low-dose for urgency/incontinence; taken 30–60 min before mealtimes
- Transanal irrigation (TAI): Peristeen irrigation system — reduces frequency/clustering; nurse training required
- Sacral nerve stimulation: Interventional option for severe/refractory LARS — urological/colorectal surgeon referral
- Psychological support — normalise symptoms; reduce social isolation
Lower Limb Lymphoedema Post-Pelvic Dissection
- Pelvic lymph node dissection/irradiation disrupts lymphatic drainage → lower limb lymphoedema
- Assessment: bilateral leg circumference measurements; heaviness/aching/skin changes
- Lymphoedema nurse specialist referral — manual lymphatic drainage (MLD)
- Compression garments (Class 2 hosiery) — measured when oedema is stable
- Skin care — emollients daily; avoid trauma/infection (cellulitis dramatically worsens lymphoedema)
- Exercise — walking, swimming, cycling — improves lymphatic flow
- Elevation at night — leg elevation above heart level
- Avoid constriction — no tight clothing/bands around limbs or waist
Fear of Cancer Recurrence (FCR)
- FCR is the most prevalent psychosocial concern post-CRC treatment — reported by 70–80% of survivors
- Screen using: Fear of Cancer Recurrence Inventory (FCRI) or single-item scale at surveillance visits
- Normalise the experience — validate that FCR is expected and common
- Cognitive-behavioural therapy (CBT) — ConquerFear programme evidence-based for severe FCR
- Surveillance schedule as structure — reduces uncertainty; educate patient on when and how to seek help with new symptoms
- Peer support groups — cancer survivor networks; important in GCC where formal cancer psychology services may be limited
- Mindfulness-based stress reduction (MBSR) — evidence for moderate benefit in cancer FCR
Genetic Testing — Lynch Syndrome & FAP
Lynch Syndrome (HNPCC)
- Caused by germline MMR mutations (MLH1, MSH2, MSH6, PMS2)
- Universal MMR/MSI testing of all CRC tumours — if MMR deficient, refer to clinical genetics
- Confirms Lynch: lifetime risk CRC 40–80%; endometrial 40–60%; ovarian 10–15%
- Cascade testing: Offer to first-degree relatives; 50% inheritance risk
- Annual colonoscopy from age 25 (or 5 years before youngest affected family member)
- Annual endometrial sampling in female Lynch carriers from age 35
- Aspirin 600mg daily — LinSSA trial evidence for Lynch cancer risk reduction
FAP (Familial Adenomatous Polyposis)
- APC gene mutation — hundreds to thousands of colonic polyps by adulthood
- Near 100% lifetime CRC risk if untreated — prophylactic colectomy indicated
- Surveillance from age 10–12 — annual flexible sigmoidoscopy
- Upper GI surveillance — duodenal/periampullary polyps (Spigelman staging)
- Desmoid tumours — abdominal mass/pain; sulindac/imatinib; surgical resection challenging
- Attenuated FAP (AFAP) — fewer polyps, later onset; MUTYH-associated polyposis (MAP) — autosomal recessive
- GCC: consanguinity increases risk of MAP and other autosomal recessive CRC syndromes
Nursing Role in Genetics: Identify family history red flags at initial assessment. Facilitate genetics referral. Support patients through genetic testing decisions (including implications for family members, insurance, cultural attitudes). Do not disclose results to family without patient consent.
Palliative Care Integration — Metastatic CRC
Liver Metastases
- Resection criteria: resectable if ≤3 segments involved, adequate future liver remnant (>25–30%), no extrahepatic disease (or controlled)
- Conversion chemotherapy (FOLFOX/FOLFIRI + targeted) to downstage to resectability
- HAI (hepatic arterial infusion) — specialist centres
- RFA (radiofrequency ablation) — small unresectable lesions
- TACE/SIRT (selective internal radiation therapy/Y-90) — non-resectable liver-dominant disease
Palliative Care & Goals of Care
- Early palliative care integration — from metastatic diagnosis; evidence improves survival and QoL
- Goals of care conversations — early, iterative, culturally sensitive in GCC
- Symptom burden assessment — ESAS/PPS at each clinic visit
- Bowel obstruction management (malignant) — NG drainage; stenting; palliative stoma
- Pain management — WHO analgesic ladder; opioid titration
- Spiritual care — chaplaincy; in GCC, Islamic spiritual care integral to holistic nursing
GCC-Specific Colorectal Cancer Context
Distinct patient demographics, cultural factors, healthcare systems, and environmental conditions shape colorectal cancer nursing practice across the Gulf Cooperation Council.
Younger Patient Population
Age at Diagnosis
- Median age at CRC diagnosis: ~52 years in Saudi Arabia vs 68 in UK/USA
- Up to 25% of GCC CRC patients are under 50 at diagnosis
- Higher proportion of left-sided, poorly differentiated, mucinous/signet ring tumours
- More aggressive biology — MSI-high more common in younger GCC patients
- Genetic predisposition higher — Lynch/FAP more prevalent due to consanguinity
Implications for Nursing Care
- Fertility preservation discussions — pre-treatment in reproductive-age patients
- Employment/financial concerns — younger patients often primary breadwinners
- Dependent children — psychosocial impact on family unit
- Body image and stoma acceptance — younger patients may struggle more
- Digital health engagement — younger patients respond well to app-based monitoring and education
- Long-term survivorship planning — 30+ year survival horizon; late effects critical
Late Presentation — Addressing Barriers
Barriers to Early Presentation
- Symptom normalisation — rectal bleeding attributed to haemorrhoids or diet
- Cultural reluctance to discuss bowel symptoms — perceived as shameful/private
- Fear of cancer diagnosis — "if I don't know, it won't be cancer"
- Disruption to family/work responsibilities
- Rural/remote access challenges — particularly in Oman, Saudi interior
- Over-reliance on traditional medicine as first-line treatment
- Religious fatalism — "it is God's will" (though this can also be a coping strength)
- Expatriate workers — fear of job loss/deportation if sick, delayed help-seeking
Nursing Strategies
- Health literacy campaigns — Arabic-language bowel cancer awareness
- Primary care nurse education — recognise red flag symptoms; urgent referral pathways
- Religious leader engagement — imams as health education champions
- Workplace health screening — especially for expat worker communities
- Female health advocates — in conservative communities, female nurses essential for women's health education
- Social media outreach — high smartphone/social media penetration in GCC
- Dedicated Arabic-language patient information for colorectal cancer
GCC Colorectal Cancer Screening Programmes
UAE National Screening Programme
- FIT (Faecal Immunochemical Test) — offered to asymptomatic adults 50–74
- Positive FIT → diagnostic colonoscopy within 6 weeks
- Abu Dhabi Breast and Colorectal Cancer Screening Programme — integrated into Thiqa/Daman insurance
- Low uptake remains a challenge — cultural barriers, inconvenience of FIT collection
- Nurse-led screening clinics — improving access
Saudi MOH CRC Screening
- Saudi Vision 2030 — preventive health emphasis; CRC screening in national cancer strategy
- FIT test offered via primary health care centres from age 50
- Colonoscopy capacity expansion — endoscopy training programmes
- National Cancer Registry — King Faisal Specialist Hospital data
- Regional variation in programme implementation — urban vs rural
Hajj & Umrah — Missed Screening Opportunity
Millions of Muslims travel to Saudi Arabia annually for Hajj and Umrah, many from countries with limited cancer screening access. With health infrastructure at Hajj sites and medical teams present, targeted CRC screening (FIT distribution) during Hajj represents an underexplored opportunity. Nurses staffing Hajj medical teams are uniquely positioned to deliver brief health interventions and FIT test distribution.
Stoma Management in Islamic Context
Wudu (Ritual Ablution) with Stoma
- Standard wudu requires cleanliness of body and absence of impurity (najasah)
- Stoma output (urine/faeces) is considered najasah — bag must be emptied/sealed before prayer
- If stoma cannot be controlled, patient is considered in a state of chronic excuse (ma'dhur) — can perform wudu once per prayer time and pray even if stoma is active
- Consultation with Islamic scholars (fatawa) available — patient should be encouraged to seek guidance
- Provide patient with official fatwa references (e.g., Saudi Islamic Affairs Ministry guidance on stoma and prayer)
Salah (Prayer) with Stoma
- 5 daily prayers — prostration requires stomal pouch to remain sealed and secure
- Convex pouching system — reduces risk of leakage during prostration
- Mini/compact pouches — less visible under clothing during prayer
- Prayer mat use — ensure pouch sealed before prayer
- Ramadan fasting: Stoma output may reduce with fasting — monitor for dehydration, especially loop ileostomy. Discuss with oncology team — some chemotherapy cycles can be adjusted around Ramadan
- Hajj/Umrah with stoma — achievable with planning; ensure adequate supply of pouching system; humidity/heat management strategies
Post-APR Perineal Wound in GCC Climate
- High ambient temperatures (up to 45–50°C summer) and humidity create challenging wound healing environment
- Moisture-wicking dressings essential — standard gauze dressings become saturated rapidly
- More frequent dressing assessment in outpatient settings — may require daily nursing visits initially
- Air conditioning in home environments — encourage patients to remain in cool environments during healing phase
- Perianal hygiene — bidet use common in GCC (and recommended); gentle irrigation post-defaecation
- Perineal wound dehiscence rates higher in irradiated field + tropical climate conditions — early VAC therapy consideration
- Community wound care nurse availability — variable across GCC; may require outpatient clinic attendance
- Patient education: signs of wound infection, haematoma, sinus formation
Traditional Herbal Treatments — Drug Interactions
Important: GCC patients commonly use traditional herbal remedies concurrently with chemotherapy. Ask specifically at every cycle — patients may not volunteer this information.
| Herbal Treatment | Common Use in GCC | Potential Interaction |
|---|
| Black Seed (Nigella sativa / Habbatus sauda) | Immune boosting, anti-cancer beliefs | Inhibits CYP3A4 — may increase concentrations of irinotecan, oxaliplatin metabolites; antiplatelet effects; additive bleeding risk with bevacizumab |
| Frankincense (Boswellia / Luban) | Anti-inflammatory, spiritual healing | Antiplatelet activity; potential CYP interaction; limited data but caution with anticoagulants |
| Sidr honey / Manuka | Wound healing, immune support | Generally safe; hyperglycaemia risk in diabetics on dexamethasone |
| Turmeric (Curcumin) | Anti-cancer, anti-inflammatory | Inhibits CYP3A4 and CYP2C9; may increase capecitabine/5-FU toxicity; antiplatelet |
| Camel milk/urine | Traditional cancer treatment | Camel urine — significant infection risk; no proven benefit; discourage strongly |
| St. John's Wort | Less common; anxiety | Potent CYP3A4 inducer — reduces irinotecan, bevacizumab efficacy significantly; CONTRAINDICATED |
Nursing approach: Take a non-judgmental stance when asking about traditional treatments. Explain that some may interfere with cancer treatment effectiveness or increase side effects — not that they are inherently wrong. Document all supplements in patient records and flag to medical team.
Oncology Nursing Workforce in GCC
Challenges
- High reliance on expatriate nurses (Philippines, India, Jordan, Egypt) — cultural and language gaps with patients
- High turnover of nursing staff — 2–3-year contracts; knowledge continuity affected
- Limited availability of oncology nursing specialist training within GCC
- Language barrier — Arabic-speaking nurses needed; translation services
- Oncology nursing is a subspecialty; general wards may lack chemotherapy training
- Moral distress — caring for young patients with advanced disease
Opportunities & Solutions
- GCC oncology nursing societies — UAE Oncology Nursing Society; Saudi oncology nursing development
- Simulation training — chemotherapy administration competency frameworks
- Mentorship programmes — senior-junior nurse pairing
- Nationalisation initiatives (Saudisation/Emiratisation) — national nurses in key roles
- Digital learning platforms — Arabic-language oncology nursing CPD
- Oncology CNS roles expansion — specialist nurse as key worker model
- International certification — ONCC OCN credential for GCC nurses